Powered by ZigaForm version
(Last Updated On: November 6, 2022)

Public Alert No: 42 – NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin 625mg

October 22, 2022,

The Agency wishes to draw the attention of the public to the detection of suspected falsified Augmentin 625mg Tablets in circulation within the country with the following details and labelling lapses;

The details of the suspected falsified Augmentin 625mg Tabs are as follows;

Product Name: Augmentin 625mg.

Batch No.: 562626

Manufacturing date: April 2021

Expiry date: April 2024.

NAFDAC Reg No: 04-1928.

Labelling Lapses

The product failed short of the labeling requirements.

  • No inscription “manufactured by” is written on the label -only the address.
  • Manufacturing and Expiry dates do not meet the acceptable format.
  • No MAS scratch number for verification.
  • The logo “gsk” is not properly positioned as on the original.

The listed information indicates the product is falsified and counterfeited

In view of the above, NAFDAC has notified all its formations in the zones and 36 states of the federation including the FCT to carry out surveillance and mop up the falsified   Augmentin tablets.

Product Images

Attached below are images of the suspected counterfeit Augmentin 625mg Tablets.

Please note that the genuine Augmentin 625mg has legible product labeling information including date markings – expiration and manufactured dates, batch number and NAFDAC registration number.

NAFDAC advise to wholesalers, distributors, and pharmacies is that medicines should be obtained from authorized/licensed suppliers, increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the falsified product. The products’ authenticity, physical condition and labels should be carefully checked. 

NAFDAC implores healthcare providers to ensure vigilance to prevent the administration of the falsified products to unsuspecting patient. Members of the public in possession of the above suspected counterfeit product are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.

Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product. Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email: sf.alert@nafdac.gov.ng  

Signed Management

Was this post helpful?